You are currently viewing 2026 Medical Cost Report – Strategies for Employers, Health Plans, Providers and Healthcare Investors
Medical Cost Strategies l in pharmacy with improved coverage rules for PBMs catastrophic loss use reasonable medical bill charges expert witness mental health observability driven interventions and ASO oversight for ERISA plans

2026 Medical Cost Report – Strategies for Employers, Health Plans, Providers and Healthcare Investors

Health plan strategy | Pharmacy spend | High-cost claims | ERISA fiduciary oversight

Medical Cost Strategies for Employers, Health Plans, Providers, and Healthcare Investors

Medical cost strategies based on UnitedHealthcare’s 2026 Health Trends Report describe a cost environment in which a small number of clinical, pharmacy, documentation, and site-of-care categories are driving a disproportionate share of medical trends. The practical question for plan sponsors, payors, providers, and investors is no longer whether costs are rising. It is where better data, better contracting, and better regulatory discipline can still change the outcome.

Pharmacy Claims, Catastrophic Claims over $100,000, Mental Health, Emergency Room Utilization, and ERISA Employer Funded Plan Fiduciary Oversight

According ot the United Healthcare report, these are the burning platforms right now in healthcare costs.  I have added my own precursors to improved medical cost strategies after each bullet.

  • Specialty pharmacy is now a classification and contracting risk. Traditional formulary and rebate strategies are not enough when a small share of utilization drives a majority of drug spend.
  • Catastrophic claims require defensible evidence. High-cost oncology, cell, gene, and molecular therapies make clinical documentation, coding accuracy, coverage criteria, and stop-loss coordination central to financial control.
  • Mental health, maternity, digestive disorders, and obesity care are converging. These categories should be governed as overlapping population-health risks, not as isolated benefit line items.
  • Site-of-care strategy is a data observability problem.  EMTALA requires that healthcare providers treat first, stabilize, and ask questions about insurance later. Avoidable emergency department use and declining virtual-care engagement require reliable claims, eligibility, EHR, and engagement data.
  • Employer strategy is moving from blunt cost shifting to governed navigation. Copay-driven designs, Centers of Excellence, integrated benefits, and advocacy solutions work only when the underlying data, contracts, and fiduciary governance are sound.

UnitedHealthcare’s 2026 Health Trends Report, based on claims incurred from November 2024 through October 2025 across UnitedHealthcare’s self-funded and fully insured book of business, presents a consistent picture: healthcare costs are rising faster than inflation, the drivers are concentrated in a small number of high-cost categories, and the levers available to employers are narrower than they were even three years ago.

The headline figures are striking. According to the report, catastrophic claims of $100,000 or more grew 12.9% from 2024 to 2025. Pharmacy costs rose 11%, with similar projections for 2026. Specialty medications account for roughly 55% of total pharmacy benefit spend despite representing less than 2% of utilization. Mental health costs have risen 117% since 2019. Cell, gene, and molecular therapies – single-administration treatments costing between $370,000 and $4 million each – are coming to market faster than many plans can build coverage, stop-loss, and audit policies around them.

These are not abstract trend lines. They are operational problems for employers, health plans, hospital systems, benefit consultants, counsel, and healthcare investors. They are also precisely the types of problems No World Borders has worked on for nearly two decades: healthcare data, regulatory governance, reimbursement economics, medical coding, benefit design, claims audit, and healthcare transaction diligence.

The pharmacy cost problem is a classification, coverage, and contracting problem

UnitedHealthcare identifies three top employer pharmacy concerns: overall pharmacy costs, the affordability of higher-cost drugs, and the use and implications of GLP-1 therapies. The deeper issue is concentration risk. When less than 2% of utilization drives roughly 55% of total pharmacy benefit spend, traditional formulary tools and rebate-driven pharmacy benefit manager contracts cannot carry the full burden of cost management.

Drug costs behave this way in part because drugs are classified, covered, and reimbursed through systems that were not designed for a world in which a single therapy can cost the equivalent of a multi-year insurance premium. NDCs, HCPCS J-codes, formulary tiers, Pharmacy and Therapeutics Committee decisions, 340B eligibility, specialty-vs.-retail channel rules, prior authorization protocols, and medical-benefit drug billing all interact. No World Borders has written on these issues in Drug Pricing Expert and Classification Systems, Pharmacy Benefit Manager Expert Witness, and Pharmacy Benefit Managers Drug Pricing and Appeals.

Operationalize specialty pharmacy governance by mapping NDC, GPI, RxNorm, and HCPCS drug identifiers to claims, formulary, prior-authorization, rebate, MAC/WAC, and medical-benefit billing data. Use that evidence to audit PBM contract performance, test UCR and reimbursement assumptions, identify spread-pricing or rebate leakage, and preserve clinically necessary access to high-cost therapies.

For employers and plan fiduciaries, the action item is clear: specialty pharmacy governance should include classification review, medical-benefit and pharmacy-benefit alignment, rebate and spread-pricing transparency, biosimilar and site-of-care strategy, GLP-1 coverage criteria, and audit rights that are specific enough to be enforced. Public data standards and reference systems such as the FDA National Drug Code Directory and NLM RxNorm illustrate why terminology, identifier mapping, and reimbursement logic must be managed together.

Catastrophic claims and gene therapies require defensible audit evidence

A 12.9% year-over-year increase in catastrophic claims is more than a trend. It is a structural shift. Cell and gene therapies, expanded oncology indications, complex neonatal care, and earlier-onset chronic conditions are pushing claims that used to be rare into the routine planning horizon for mid-sized and large employers.

Centers of Excellence, prior authorization, case management, and stop-loss coverage can mitigate this risk, but only when the underlying clinical evidence is defensible. A high-cost claim should be evaluated against the medical record, plan language, medical necessity criteria, applicable coverage policies, ICD-10-CM/PCS and CPT coding, drug and device identifiers, and any stop-loss notification or reimbursement conditions. The FDA’s cellular and gene therapy resources show how quickly this category continues to develop. Medicare coverage resources such as CMS Local Coverage Determinations and the CMS Medicare Coverage Database also underscore the importance of linking clinical indications, documentation, coding, and coverage rules.

No World Borders has provided expert opinions on more than $2 billion in medical reimbursements and has led investor diligence on more than $8 billion in healthcare mergers and acquisitions. Across that work, the pattern is consistent: the difference between a defensible high-cost claim and a recoverable or contestable one is often documentation quality, coding accuracy, medical necessity support, and contract language. Our firm provides specialized opinions on Usual, Customary, and Reasonable (UCR) charges for medical bills in personal injury and medical malpractice cases, as well as expert analysis of reasonable reimbursement rates in disputes between healthcare providers and health plans. Our claims, reimbursement, and coding work is reflected in resources such as Medical Billing Expert Witness, ICD-10 Consulting, and Solutions Across the Continuum of Care.

Mental health, maternity, and comorbidity require integrated benefit governance

UnitedHealthcare reports that mental health costs have risen 117% since 2019, maternity costs rose 11.7% from 2024 to 2025, and digestive disorders rose 10.5%, partly as a downstream effect of GLP-1 utilization. These categories should not be analyzed in isolation. They are signals of a workforce in which complex and chronic conditions are presenting earlier, clustering with one another, and interacting with access, affordability, and site-of-care decisions.

How No World Borders can help: Treat mental health, maternity, digestive disorders, and obesity-related spending as connected population-health analytics signals, not isolated benefit categories. No World Borders can help employers, health plans, providers, and investors integrate claims, EHR, pharmacy, and X12 transaction data; evaluate DSM-5, ICD-10, and behavioral-health coding alignment; and use data quality, analytics, and AI-enabled observability to identify comorbidity clusters, access gaps, site-of-care leakage, and opportunities for targeted micro-interventions before conditions become high-cost claims.  Consider observability-driven interventions in consumer-facing content.

My postgraduate work at Stanford Medical School in Biomedical Informatics and at Harvard Medical School in Clinical Bioethics, Risk Management, and Addiction Medicine has shaped how No World Borders approaches these categories. We have worked with behavioral health EHR vendors on DSM-5 and ICD-10 alignment, advised on prior authorization and coverage determinations, and consulted on the data and policy infrastructure needed to support population-health programs that move outcomes rather than simply move utilization.

ER overutilization and site-of-care decisions require data observability

UnitedHealthcare reports that emergency room visits rose 2.1% while virtual visits fell 16.1%, and that Gen Z relies on the ER more than any other generation while using primary care the least.

This is fundamentally a data observability and engagement problem. Employers and plans need to know whether claims, eligibility, provider directory, care navigation, virtual care, and EHR event data are complete, timely, mapped correctly, and actionable. Furthermore, it is incumbent on all trading partners across the healthcare ecosystem, including health plans such as UnitedHealthcare and healthcare providers, to ensure the accuracy and integrity of the data they exchange. Maintaining high standards for data quality is a shared responsibility that serves as the foundation for effective plan governance and improved member outcomes. AHRQ maintains emergency department research, data, and tools, while Telehealth.HHS.gov tracks telehealth trends, data, and research. Those resources reinforce the same point: the site-of-care strategy depends on usable information, not just member communications.

No World Borders applies data observability principles to claims, eligibility, EHR, and X12 transaction data, including 837, 835, 270, and 271 workflows. The five pillars of data observability – data quality monitoring, pipeline observability, infrastructure monitoring, user observability, and cost optimization – map directly onto the infrastructure plans and employers need to identify high-risk members, route them to appropriate care, and measure whether engagement programs are working. This work aligns with our broader Data Analytics for Healthcare, HIPAA Privacy, and HIPAA Privacy and Security capabilities.

Employer strategy is shifting from blunt cost-sharing to governed navigation

UnitedHealthcare’s data shows employers moving away from full-replacement HDHP/CDHP designs and toward copay-driven plan designs, Centers of Excellence, integrated benefits, and higher-level advocacy solutions. The shift is logical. When the most expensive categories are specialty drugs, catastrophic claims, complex comorbidities, and avoidable site-of-care decisions, a higher deductible alone does not solve the problem. It may simply move costs to members without improving clinical or financial outcomes.

The next generation of employer health plan strategy should combine benefit design with fiduciary oversight, vendor governance, data rights, claims audit rights, and measurable performance guarantees. The Department of Labor’s fiduciary responsibility resources and Form 5500 resources are important reminders that employee benefit plans are governance structures, not merely annual procurement exercises. No World Borders’ ERISA resources, including ERISA Expert Witness and Form 5500 under ERISA, address the same governance foundation.

For investors, the implication is equally important. A healthcare IT, payor, provider, specialty pharmacy, care navigation, or risk-bearing platform cannot be evaluated only on revenue growth. Diligence should examine claims integrity, coding risk, medical necessity workflows, PBM and specialty pharmacy exposure, privacy and security controls, risk adjustment methods, HEDIS and quality-measure infrastructure, and the degree to which reported savings are auditable. No World Borders has advised health plans, providers, healthcare IT companies, law firms, self-insured employers, and investors across these domains.

Where No World Borders fits

The UnitedHealthcare report is, in effect, a map of the cost-containment work that health plans, self-insured employers, hospital systems, healthcare vendors, and investors need to be doing in 2026 and 2027. At No World Borders, we have spent nearly two decades building the regulatory, data, and economic expertise needed to do that work across:

  • ERISA plan administration, fiduciary oversight, service-provider governance, and Form 5500-related review;
  • HIPAA Privacy and Security, HITECH safeguards, recognized cybersecurity practices, and healthcare data governance;
  • Medicare Advantage risk adjustment, HEDIS quality measures, RADV and RAC audit defense, RAPS and encounter data analytics, and Medical Loss Ratio analytics;
  • Specialty and prescription drug pricing, PBM contracting, formulary design, rebate and spread-pricing analysis, and 340B economics;
  • Clinical documentation improvement, medical coding audits, medical necessity review, and revenue cycle analytics;
  • Investor diligence on healthcare IT, payor, provider, revenue cycle, specialty pharmacy, and healthcare services transactions; and
  • AI, data observability, claims analytics, EHR audits, and X12 transaction analysis.

If your organization is reading the 2026 Health Trends Report and recognizing that the strategies that worked in 2022 will not be sufficient for 2026 and 2027, the next step is to focus on the categories that drive the majority of spend: specialty pharmacy, catastrophic claims, comorbid behavioral and medical conditions, avoidable emergency department use, and vendor performance. These are the categories where better contracts, better data, and better documentation discipline can still bend the curve.

Practical next steps for plan sponsors, payors, and investors

Organizations responding to these trends should begin with a focused diagnostic: identify the claims categories driving the majority of spend; review PBM, specialty pharmacy, TPA, stop-loss, care navigation, and Centers of Excellence contracts; test coding and documentation quality on high-cost claims; evaluate compliance with ERISA, HIPAA, parity, and coverage requirements; and confirm that data feeds are accurate enough to support real-time intervention.

For assistance with healthcare data, regulatory, reimbursement, coding, claims audit, ERISA, HIPAA, PBM, or healthcare investor diligence matters, contact No World Borders.

Michael F. Arrigo is Managing Partner of No World Borders, a healthcare data, regulatory, and economic consulting firm based in Newport Beach, California. He has served as a testifying expert in federal and state courts, has been quoted in The Wall Street Journal, Kaiser Health News, NPR, Forbes, and USA Today, and currently serves on the Board of Directors of MSP Recovery. Reach

Michael F. Arrigo

Michael Arrigo, an expert witness, and healthcare executive, brings four decades of experience in the software, financial services, and healthcare industries. In 2000, Mr. Arrigo founded No World Borders, a healthcare data, regulations, and economics firm with clients in the pharmaceutical, medical device, hospital, surgical center, physician group, diagnostic imaging, genetic testing, health I.T., and health insurance markets. His expertise spans the federal health programs Medicare and Medicaid and private insurance. He advises Medicare Advantage Organizations that provide health insurance under Part C of the Medicare Act. Mr. Arrigo serves as an expert witness regarding medical coding and billing, fraud damages, and electronic health record software for the U.S. Department of Justice. He has valued well over $1 billion in medical billings in personal injury liens, malpractice, and insurance fraud cases. The U.S. Court of Appeals considered Mr. Arrigo's opinion regarding loss amounts, vacating, and remanding sentencing in a fraud case. Mr. Arrigo provides expertise in the Medicare Secondary Payer Act, Medicare LCDs, anti-trust litigation, medical intellectual property and trade secrets, HIPAA privacy, health care electronic claim data Standards, physician compensation, Anti-Kickback Statute, Stark law, the Affordable Care Act, False Claims Act, and the ARRA HITECH Act. Arrigo advises investors on merger and acquisition (M&A) diligence in the healthcare industry on transactions cumulatively valued at over $1 billion. Mr. Arrigo spent over ten years in Silicon Valley software firms in roles from Product Manager to CEO. He was product manager for a leading-edge database technology joint venture that became commercialized as Microsoft SQL Server, Vice President of Marketing for a software company when it grew from under $2 million in revenue to a $50 million acquisition by a company now merged into Cincom Systems, hired by private equity investors to serve as Vice President of Marketing for a secure email software company until its acquisition and multi $million investor exit by a company now merged into Axway Software S.A. (Euronext: AXW.PA), and CEO of one of the first cloud-based billing software companies, licensing its technology to Citrix Systems (NASDAQ: CTXS). Later, before entering the healthcare industry, he joined Fortune 500 company Fidelity National Financial (NYSE: FNF) as a Vice President, overseeing eCommerce solutions for the mortgage banking industry. While serving as a Vice President at Fortune 500 company First American Financial (NYSE: FAF), he oversaw eCommerce and regulatory compliance technology initiatives for the top ten mortgage banks and led the Sarbanes Oxley Act Section 302 internal controls I.T. audit for the company, supporting Section 404 of the Sarbanes Oxley Act. Mr. Arrigo earned his Bachelor of Science in Business Administration from the University of Southern California. Before that, he studied computer science, statistics, and economics at the University of California, Irvine. His post-graduate studies include biomedical ethics at Harvard Medical School, biomedical informatics at Stanford Medical School, blockchain and crypto-economics at the Massachusetts Institute of Technology, and training as a Certified Professional Medical Auditor (CPMA). Mr. Arrigo is qualified to serve as a director due to his experience in healthcare data, regulations, and economics, his leadership roles in software and financial services public companies, and his healthcare M&A diligence and public company regulatory experience. Mr. Arrigo is quoted in The Wall Street Journal, Fortune Magazine, Kaiser Health News, Consumer Affairs, National Public Radio (NPR), NBC News Houston, USA Today / Milwaukee Journal Sentinel, Medical Economics, Capitol ForumThe Daily Beast, the Lund Report, Inside Higher Ed, New England Psychologist, and other press and media outlets. He authored a peer-reviewed article regarding clinical documentation quality to support accurate medical coding, billing, and good patient care, published by Healthcare Financial Management Association (HFMA) and published in Healthcare I.T. News. Mr. Arrigo serves as a member of the board of directors of a publicly traded company in the healthcare and data analytics industry, where his duties include: member, audit committee; chair, compensation committee; member, special committee.

Leave a Reply